Clarity Pharmaceuticals (CU6) Corporate presentation summary

Vision and strategy

• Aims to build a leading pharmaceutical biotech based on Australian scientific IP, targeting blockbuster markets with high unmet needs.

• Focuses on discovery, rigorous clinical development, and commercialisation of innovative radiopharmaceuticals.

Key products and pipeline

• Lead product 64Cu/67Cu-SAR-bisPSMA targets prostate cancer, offering both diagnostic and therapeutic applications.

• Three FDA Fast Track designations granted for diagnostic and therapeutic indications in prostate cancer.

• Pipeline includes SARTATE for neuroendocrine tumours, SAR-bisFAP for pan-cancer theranostics, and SAR-Bombesin for PSMA-negative prostate cancer.

Clinical trial highlights

• 64Cu-SAR-bisPSMA outperformed standard PSMA PET agents in lesion detection, uptake, and tumour-to-background ratio in multiple Phase I-III trials.

• Next-day imaging with 64Cu-SAR-bisPSMA significantly increased lesion detection and changed clinical management in a high proportion of patients.

• 67Cu-SAR-bisPSMA therapy showed high PSA response rates and complete responses in metastatic castration-resistant prostate cancer with a favourable safety profile.

• SARTATE demonstrated improved lesion detection and sensitivity over 68Ga-DOTATATE in neuroendocrine tumours.